Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10376745" target="_blank" >RIV/00216208:11130/18:10376745 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/18:10376745
Result on the web
<a href="https://doi.org/10.1038/s41375-018-0179-9" target="_blank" >https://doi.org/10.1038/s41375-018-0179-9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-018-0179-9" target="_blank" >10.1038/s41375-018-0179-9</a>
Alternative languages
Result language
angličtina
Original language name
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
Original language description
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib upfront (300, 400, 500 mg/m(2), respectively) within a prospective phase III trial. Therapy response, progression-free survival, causes of treatment failure, and side effects were analyzed in 148 children and adolescents with complete data. Event-free survival rate by 18 months for patients in CML-CP (median follow-up time 25 months, range: 1-120) was 97% (95% CI, 94.2-99.9%). According to the 2006 ELN-criteria complete hematologic response by month 3, complete cytogenetic response (CCyR) by month 12, and major molecular response (MMR) by month 18 were achieved in 98, 63, and 59% of the patients, respectively. By month 36, 86% of the patients achieved CCyR and 74% achieved MMR. Thirty-eight patients (27%) experienced imatinib failure because of unsatisfactory response or intolerance (N = 9). In all, 28/148 patients (19%) underwent stem cell transplantation (SCT). In the SCT sub-cohort 2/23 patients diagnosed in CML-CP, 0/1 in CML-AP, and 2/4 in CML-BP, respectively, died of relapse (N = 3) or SCT-related complications (N = 2). This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia
ISSN
0887-6924
e-ISSN
—
Volume of the periodical
32
Issue of the periodical within the volume
7
Country of publishing house
GB - UNITED KINGDOM
Number of pages
13
Pages from-to
1657-1669
UT code for WoS article
000438062500017
EID of the result in the Scopus database
2-s2.0-85048725252